LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Ligand Pharmaceuticals Inc

Fechado

SetorSaúde

181.99 -0.62

Visão Geral

Variação de preço das ações

24h

Atual

Mín

179.25

Máximo

185.95

Indicadores-chave

By Trading Economics

Rendimento

112M

117M

Vendas

115M

P/E

Médio do Setor

81.352

77.671

Margem de lucro

101.569

Funcionários

68

EBITDA

87M

149M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+31.03% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-485M

3.6B

Abertura anterior

182.61

Fecho anterior

181.99

Sentimento de Notícias

By Acuity

56%

44%

329 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de dez. de 2025, 22:02 UTC

Ganhos

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 de dez. de 2025, 21:46 UTC

Ganhos

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 de dez. de 2025, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 de dez. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 de dez. de 2025, 23:36 UTC

Conversa de Mercado

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 de dez. de 2025, 23:20 UTC

Ganhos

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 de dez. de 2025, 23:15 UTC

Ganhos

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 de dez. de 2025, 22:59 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 de dez. de 2025, 22:45 UTC

Conversa de Mercado

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 de dez. de 2025, 22:40 UTC

Ganhos

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 de dez. de 2025, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 de dez. de 2025, 22:06 UTC

Ganhos

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 de dez. de 2025, 22:02 UTC

Ganhos

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 de dez. de 2025, 22:00 UTC

Ganhos

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 de dez. de 2025, 21:53 UTC

Ganhos

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 de dez. de 2025, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 de dez. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

10 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

10 de dez. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 de dez. de 2025, 21:33 UTC

Ganhos

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 de dez. de 2025, 21:32 UTC

Ganhos

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 de dez. de 2025, 21:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 de dez. de 2025, 21:25 UTC

Ganhos

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 de dez. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 de dez. de 2025, 21:16 UTC

Ganhos

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 de dez. de 2025, 21:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 de dez. de 2025, 21:15 UTC

Ganhos

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 de dez. de 2025, 21:14 UTC

Ganhos

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 de dez. de 2025, 21:14 UTC

Ganhos

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparação entre Pares

Variação de preço

Ligand Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

31.03% parte superior

Previsão para 12 meses

Média 243.5 USD  31.03%

Máximo 275 USD

Mínimo 220 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Ligand Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

102.5 / 109.24Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

329 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat